CLL therapeutics: Key market research findings
- Special regulatory designations drive market growth
- The Americas dominate the market geographically
- Key vendors—F. Hoffmann-La Roche, AbbVie, Teva Pharmaceuticals, Johnson & Johnson, Gilead Sciences, and Novartis
Technavio’s market research analysts predict the global CLL therapeutics market to grow at a CAGR of over 19% between 2016 and 2020. Special regulatory designations are the primary driver for growth in this market. Diseases that affect a small percentage of the population, such as chronic lymphocytic leukemia (CLL), are treated by limited marketed drugs. It may not be profitable for companies to develop these drugs as research and development (R&D) recovery may not be feasible due to the small patient base. In an attempt to compensate for this drawback and boost the development of such drugs, regions such as the US and the EU award an Orphan Drug Designation or Breakthrough Therapy Designation to certain drugs. The Americas occupied more than 54% of the market space to dominate the global CLL therapeutics market in 2015. The introduction of novel drugs and the increasing demand from emerging markets such as Mexico and Brazil are some of the factors that will fuel growth in the CLL therapeutics market in the Americas during the forecast period.
The new market research report from Technavio presents a breakdown and analysis of the CLL therapeutics segments based on the route of administration (ROA).
“Joint ventures and partnerships is an ongoing trend in the market. Vendors are increasingly forming strategic alliances to strengthen their foothold in the market. Co-development agreements enable the sharing of regulatory and developmental experiences gained by either company to support the pipeline candidates. Such associations can prove to be highly beneficial as the distribution channels of both the development partners can be utilized in commercializing the drug. Moreover, these ensure the in-flow of adequate funds as well as decreases the liability of individual organizations in case of failures, thereby attracting more venture capital investors,” says Barath Palada, Lead Analyst, Healthcare & Lifesciences, Technavio Research.
During 2015, the parenteral route of administration (ROA) accounted for over 84% of the market share to dominate the global CLL therapeutics market. In the parenteral ROA, the drug is administered through intravenous, subcutaneous, intrathecal, or intramuscular routes. Parenteral ROA enables rapid drug absorption followed by a fast onset of action. Parenteral ROA is the preferred route of drug administration during emergencies when there is a greater need for patient compliance and during instances where the prolonged action of the drug is required. Some drugs administered through this route to treat CLL are Rituxan/MabThera, Gazyva, Treanda, and Arzerra.
The key vendors in the global CLL therapeutic market include F. Hoffmann-La Roche, AbbVie, Teva Pharmaceuticals, Johnson & Johnson, Gilead Sciences, and Novartis. The global CLL therapeutics market is highly competitive owing to the presence of several international and regional players in the market. Since the market has enormous growth opportunities, new vendors will have a chance to explore the market. The level of competition among the providers is expected to intensify as they enter into strategic alliances and partnerships to enhance their market presence.
A more detailed analysis is available in the Technavio report, Global CLL Therapeutics Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
